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Abstract Mononuclear 5-(4-pyridyl)-10,15,20-triphenyl-
porphyrin and 5-(3-pyridyl)-10,15,20-triphenylporphyrin
as well as tetranuclear 5,10,15,20-tetra(4-pyridyl)porphy-
rin (tetra-4-pp) and 5,10,15,20-tetra(3-pyridyl)porphyrin)
(tetra-3-pp) arene ruthenium(II) derivatives (arene is
C6H5Me or p-Pr
iC6H4Me) were prepared and evaluated as
potential dual photosensitizers and chemotherapeutics in
human Me300 melanoma cells. In the absence of light, all
tetranuclear complexes were cytotoxic (IC50 B 20 lM),
while the mononuclear derivatives were not (IC50 C
100 lM). Kinetic studies of tritiated thymidine and tritiated
leucine incorporations in cells exposed to a low concen-
tration (5 lM) of tetranuclear p-cymene derivatives
demonstrated a rapid inhibition of DNA synthesis, while
protein synthesis was inhibited only later, suggesting arene
ruthenium–DNA interactions as the initial cytotoxic pro-
cess. All complexes exhibited phototoxicities toward
melanoma cells when exposed to laser light of 652 nm. At
low concentration (5 lM), LD50 of the mononuclear
derivatives was between 5 and 10 J/cm2, while for the
tetranuclear derivatives LD50 was approximately 2.5 J/cm
2
for the [Ru4(g
6-arene)4(tetra-4-pp)Cl8] complexes and less
than 0.5 J/cm2 for the [Ru4(g
6-arene)4(tetra-3-pp)Cl8]
complexes. Examination of cells under a fluorescence
microscope revealed the [Ru4(g
6-arene)4(tetra-4-pp)Cl8]
complexes as cytoplasmic aggregates, whereas the [Ru4(g
6-
arene)4(tetra-3-pp)Cl8] complexes were homogenously
dispersed in the cytoplasm. Thus, these complexes present
a dual synergistic effect with good properties of both the
arene ruthenium chemotherapeutics and the porphyrin
photosensitizer.
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Introduction
Combined therapies to treat serious diseases have become a
standard method to improve efficiency and to decrease side
effects [1–4], or to prevent resistance mechanisms com-
monly found in classic chemotherapeutic protocols [5].
Thus, in cancer treatment, a combination of different
classes of chemotherapeutic agents or a combination of
chemotherapeutics with radiation is now a common form
of treatment.
Photodynamic therapy is one of these emergent cancer
treatments. It requires the activation of a photosensitizer by
light at specific wavelengths. The excited photosensitizer
interacts with intracellular oxygen to produce singlet oxygen
and radical species, inducing direct tumor cell death,
immune response, and damage to tumor vasculature [6].
Photosensitizers usually possess a tetrapyrrolic structure
such as porphyrin derivatives and have been shown to con-
centrate in cancer cells [7–9]. To improve their cellular
uptake and phototoxicities, photosensitizers have been
coupled to a wide range of molecules. Complexes of por-
phyrins (hematoporphyrin, tetraphenylporphyrin) coor-
dinated to platinum derivatives (such as cisplatin or
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oxaliplatin) were developed a few years ago to combine the
cytotoxicity of platinum with the photodynamic activity of
porphyrins with promising anticancer effects [10–14].
However, platinum derivatives are associated with high
toxicity and resistance mechanisms [15]; therefore, the use of
a different metal is very appealing to overcome the draw-
backs associated with platinum [16, 17]. Ruthenium is an
attractive alternative to platinum, since ruthenium com-
pounds are known to display less general toxicity than their
platinum counterparts [18], but are also able to interact with
DNA and proteins [19]. With the goal to combine the pho-
todynamic action of porphyrins and the cytotoxicity of
ruthenium complexes, we have recently coordinated arene
ruthenium moieties to 5,10,15,20-tetra(4-pyridyl)porphyrin
(tetra-4-pp) [20]. The compounds obtained have good cy-
totoxicities and phototoxicities toward human melanoma
cancer cells. To optimize their structure and to better
understand their mechanisms of action in human melanoma
cells, we have now synthesized a new series of arene ruthe-
nium porphyrin compounds containing either one or four
arene ruthenium units (arene is C6H5Me or p-Pr
iC6H4Me)
coordinated to 4-pyridylporphyrin or 3-pyridylporphyrin
photosensitizer derivatives: 5-(4-pyridyl)-10,15,20-triphen-
ylporphyrin (mono-4-pp); 5-(3-pyridyl)-10,15,20-triphenyl
porphyrin (mono-3-pp); tetra-4-pp; 5,10,15,20-tetra(3-pyri-
dyl)porphyrin (tetra-3-pp). The effect of these complexes
was assessed as dual chemotherapeutics and photothera-
peutics in human Me300 melanoma cells as a model of
metastatic cancer associated with a poor prognosis.
Materials and methods
Materials
All organic solvents were degassed and saturated with nitro-
gen prior to use. The pyridylporphyrin derivatives (mono-4-
pp, mono-3-pp, tetra-4-pp, and tetra-3-pp) were purchased
from Porphyrin Systems, Germany. [Ru(g6-C6H5Me)
Cl2]2, [Ru(g
6-p-PriC6H4Me)Cl2]2, [Ru4(g
6-C6H5Me)4(tetra-
4-pp)Cl8] (5), [Ru4(g
6-p-PriC6H4Me)4(tetra-4-pp)Cl8] (6),
[Ru(g6-C6H5Me)(C6H5N)Cl2] (9), and [Ru(g
6-p-PriC6H4Me)
(C6H5N)Cl2] (10) were prepared according to published
methods [20–22].
Syntheses
[Ru(g6-C6H5Me)(mono-4-pp)Cl2]
A mixture of [Ru(g6-C6H5Me)Cl2]2 (17 mg, 0.032 mmol)
and mono-4-pp (40 mg, 0.064 mmol) was refluxed in dry
methanol (20 ml) for 4 h. In refluxing methanol the only
slightly soluble mono-4-pp dissolved completely as the
reaction progressed, while the [Ru(g6-C6H5Me)(mono-4-
pp)Cl2] (1) product precipitated as a brownish purple solid.
The solid was filtered and washed with diethyl ether and
dried in vacuo. Yield 45 mg, 80%. 1H NMR (CD2Cl2,
400 MHz): d (ppm) = 9.46 (dd, 2H, 3JH–H = 5.12 Hz,
4JH–H = 1.48 Hz, Hpyridyl), 8.96 (d, 2H, Hpyridyl), 8.89 (s,
8H, Hpyrrole), 8.27–8.23 (m, 6H, Hphenyl), 7.82 (m, 9H,
Hphenyl), 5.87 (m, 3H, Harene), 5.48 (d, 2H,
3JH–H =
5.88 Hz, Harene), 2.33 (s, 3H, CH3), -2.84 (s, 2H, NH). IR
(cm-1): 1,717 (w), 1,609 (s), 1,473 (m), 1,441 (m), 966 (s),
805 (s), 758 (m), 730 (s), 702 (s). Electrospray ionization
mass spectrometry (ESI–MS) (CH3CN/CHCl3): m/z =
844.2 [1–Cl]?. Elemental analysis (%) calc. for
C50H37N5Cl2Ru: C 68.19, H 4.24, N 7.96; found: C 68.15,
H 4.00, N 7.91.
[Ru(g6-p-PriC6H4Me)(mono-4-pp)Cl2]
[Ru(g6-p-PriC6H4Me)(mono-4-pp)Cl2] (2) was prepared as
described for 1 using [Ru(g6-p-PriC6H4Me)Cl2]2 (20 mg,
0.032 mmol) and mono-4-pp (40 mg, 0.064 mmol). Yield
40 mg, 67%. 1H NMR (CD2Cl2, 400 MHz): d (ppm) = 9.45
(dd, 2H, 3JH–H = 5.12 Hz,
4JH–H = 1.44 Hz, Hpyridyl), 8.97
(d, 2H, Hpyridyl), 8.88 (s, 8H, Hpyrrole), 8.25 (m, 6H, Hphenyl),
7.82 (m, 9H, Hphenyl), 5.66 (d, 2H,
3JH–H = 6.08 Hz, Harene),
5.44 (d, 2H, Harene), 3.15 (sept, 1H,
3JH–H = 6.84 Hz, CH),
2.28 (s, 3H, CH3), 1.46 (d, 6H, CH3), -2.83 (s, 2H, NH). IR
(cm-1): 1,717 (w), 1,650 (s), 1,508 (m), 1,458 (m), 970 (s),
800 (s), 760 (m), 730 (m). ESI–MS (CH3CN/CHCl3):
m/z = 886.2 [2–Cl]?. Elemental analysis (%) calc. for
C53H43N5Cl2Ru: C 69.05, H 4.70, N 7.63; found: C 69.08,
H 4.85, N 7.41.
[Ru(g6-C6H5Me)(mono-3-pp)Cl2]
[Ru(g6-C6H5Me)(mono-3-pp)Cl2] (3) was prepared as
described for 1 using [Ru(g6-C6H5Me)Cl2]2 (17 mg,
0.032 mmol) and mono-3-pp (40 mg, 0.065 mmol). Yield
30 mg, 53%. 1H NMR (CD2Cl2, 400 MHz): d (ppm) = 9.95
(d, 1H, 4JH–H = 2.20 Hz, Hpyridyl), 9.49 (dd, 1H,
3JH–H = 5.84 Hz, Hpyridyl), 8.99 (d, 1H,
3JH–H = 4.64 Hz,
Hpyridyl), 8.91 (s, 8H, Hpyrrole), 8.66 (dd, 1H, Hpyridyl), 8.25
(m, 6H, Hphenyl), 7.82 (m, 9H, Hphenyl), 5.72 (m, 3H, Harene),
5.57 (m, 2H, Harene), 2.17 (s, 3H, CH3), -2.83 (s, 2H, NH). IR
(cm-1): 1718 (w), 1595 (m), 1474 (m), 1440 (m), 1350 (m),
966 (s), 799 (s), 730 (m), 702 (s). ESI–MS (CH3CN/CHCl3):
m/z = 844.2 [3–Cl]?. Elemental analysis (%) calc. for
C50H37N5Cl2Ru: C 68.19, H 4.24, N 7.96; found: C 68.39,
H 4.33, N 7.96.
2
[Ru(g6-p-PriC6H4Me)(mono-3-pp)Cl2]
[Ru(g6-p-PriC6H4Me)(mono-3-pp)Cl2] (4) was prepared as
described for 1 using [Ru(g6-p-PriC6H4Me)Cl2]2 (20 mg,
0.032 mmol) and mono-3-pp (40 mg, 0.064 mmol). Yield
35 mg, 58%. 1H NMR (CD2Cl2, 400 MHz): d (ppm) = 9.92
(d, 1H, 4JH–H = 1.96 Hz, Hpyridyl), 9.47 (dd, 1H,
3JH–H = 5.68 Hz, Hpyridyl), 8.99 (d, 1H,
3JH–H = 4.84 Hz,
Hpyridyl), 8.91 (s, 8H, Hpyrrole), 8.64 (dd, 1H, Hpyridyl), 8.25
(m, 6H, Hphenyl), 7.82 (m, 9H, Hphenyl), 5.55 (d, 2H,
3JH–H = 6.16 Hz, Harene), 5.29 (d, 2H, Harene), 3.01 (sept,
1H, 3JH–H = 7.04 Hz, CH), 2.12 (s, 3H, CH3), 1.32 (d, 6H,
CH3), -2.83 (s, 2H, NH). IR (cm
-1): 1,717 (w), 1,624 (w),
1,508 (m), 1,474 (m), 967 (s), 800 (s), 731 (m), 702 (s). ESI–
MS (CH3CN/CHCl3): m/z = 886.2 [1–Cl]
?. Elemental
analysis (%) calc. for C53H43N5Cl2Ru: C 69.05, H 4.70,
N 7.63; found: C 69.10, H 4.78, N 7.30.
[Ru4(g
6-C6H5Me)4(tetra-3-pp)Cl8]
[Ru4(g
6-C6H5Me)4(tetra-3-pp)Cl8] (7) was prepared as
described for 1 using [Ru(g6-C6H5Me)Cl2]2 (70 mg,
0.13 mmol) in excess and tetra-3-pp (40 mg, 0.064 mmol).
Yield 85 mg, 77%. 1H NMR (dimethyl sulfoxide-d6,
DMSO-d6,, 400 MHz): d (ppm) = 9.41 (d, 4H,
3JH–H =
5.08 Hz, Hpyridyl), 9.09 (d, 4H,
4JH–H = 1.48 Hz, Hpyridyl),
8.90 (s, 8H, Hpyrrole), 8.70 (d, 4H,
3JH–H = 6.54 Hz, Hpyridyl),
7.94 (dd, 4H, Hpyridyl), 5.98 (m, 8H, Harene), 5.71 (m, 12H,
Harene), 2.14 (s, 12H, CH3), -2.96 (s, 2H, NH). IR (cm
-1):
1,717 (w), 1,637 (s), 1,508 (s), 1,458 (m), 1,406 (s), 968 (m),
796 (m), 730 (w), 702 (w). ESI-MS (CH3CN/CHCl3):
m/z = 492.9 [7–C6H5Me–3 Cl]
3?. Elemental analysis (%)
calc. for C68H58N8Cl8Ru4: C 48.76, H 3.49, N 6.69; found:
C 48.39, H 3.40, N 6.77.
[Ru4(g
6-p-PriC6H4Me)4(tetra-3-pp)Cl8]
[Ru4(g
6-p-PriC6H4Me)4(tetra-3-pp)Cl8] (8) was prepared as
described for 1 using [Ru(g6-p-PriC6H4Me)Cl2]2 (60 mg,
0.098 mmol) in excess and tetra-3-pp (30 mg, 0.049 mmol).
Yield 70 mg, 78%. 1H NMR (CD2Cl2, 400 MHz): d
(ppm) = 9.93 (d, 4H, 3JH–H = 7.76 Hz, Hpyridyl), 9.48 (d,
4H, 4JH–H = 1.08 Hz, Hpyridyl), 9.06 (s, 8H, Hpyrrole), 8.68 (d,
4H, 3JH–H = 7.00 Hz, Hpyridyl), 7.85 (dd, 4H, Hpyridyl), 5.56
(d, 8H, 3JH–H = 5.92 Hz, Harene), 5.32 (d, 8H, Harene), 3.02
(sept, 4H, 3JH–H = 6.68 Hz, CH), 2.15 (s, 12H, CH3), 1.32
(s, 24H, CH3), -2.90 (s, 2H, NH). IR (cm
-1): 1717 (w),
1,682 (m), 1,637 (s), 1,508 (s), 1,458 (s), 1,406 (s), 970 (m),
795 (m), 730 (w). ESI–MS (CH3CN/CHCl3): m/z = 578.9
[8–3 Cl]3?. Elemental analysis (%) calc. for C80H82
N8Cl8Ru4: C 52.12, H 4.48, N 6.08; found: C 52.53, H 4.52,
N 6.03.
Spectroscopic methods
NMR spectra were recorded using a Varian 400 MHz
spectrometer. IR spectra were recorded in KBr pellets with
a PerkinElmer 1720X Fourier transform IR spectrometer
(4,000–400 cm-1). Microanalyses were performed by the
Laboratory of Pharmaceutical Chemistry, University of
Geneva (Switzerland). Electrospray mass spectra were
obtained in positive-ion mode with a Finnigan LCQ mass
spectrometer (University of Fribourg, Switzerland). UV–
vis absorption spectra were recorded using a Uvikon 930
spectrophotometer. Quantum yields were assessed after
excitation at 414 nm. Fluorescence quantum yields at
648 nm were determined using a PerkinElmer LS50
spectrofluorometer. The singlet oxygen quantum yield was
determined using the singlet oxygen specific fluorescence
at 1,270 nm monitored by a liquid-nitrogen-cooled ger-
manium detector (model EO-817L, North Coast Scientific)
from the DCPR facility, ENSIC, Nancy, France.
Cell culture
Human Me300 melanoma cells were kindly provided by
D. Rimoldi (Ludwig Institute of Cancer Research, Lausanne
branch, Switzerland). All cell culture reagents were
obtained from Gibco-BRL (Basel, Switzerland). The cells
were grown in RPMI 1640 medium containing 10% of heat-
inactivated fetal calf serum and penicillin/streptomycin.
The organometallic complexes were dissolved in DMSO as
the stock solution and then diluted in complete medium to
the required concentration immediately prior to use. The
final DMSO concentration never exceeded 1% v/v and this
concentration did not show any effects on cell viability
(results not shown).
Determination of dark cytotoxicity
Cells were grown in 48-well cell culture plates (Corning,
NY, USA) until they were 20% confluent. The culture
medium was replaced with complete medium containing
the ruthenium complexes for concentrations from 0 to
100 lM and the cells were exposed to the complexes for
72 h. Thereafter, cell survival was measured using the
alamarBlue test as previously described [23, 24]. In
accordance with the manufacturer‘s instructions, alamar-
Blue solution (AbD Serotec, Oxon, UK) was added at 10%
v/v and incubation was continued for 2 h. Fluorescence
intensities of the cell culture supernatants were assessed
using a fluorescence microplate reader (Cytofluor,
PerSeptive BioSystems, Switzerland) at excitation and
emission wavelengths of 530 and 580 nm, respectively.
The values for treated cells were compared with the values
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for control cells incubated without complexes. Experiments
were conducted in triplicate wells and repeated at least
twice.
Kinetic evaluation of DNA and protein syntheses
Thymidine incorporation and leucine incorporation were
used to assess DNA and protein synthesis, respectively, as
previously described [25]. Cells were grown in 48-well cell
culture plates (Corning, NY, USA) until they were 20%
confluent. The culture medium was replaced with complete
medium containing the ruthenium complexes at 5 lM
concentration and cells were exposed to the complexes for
different times (0–72 h). Cell survival and tritiated thy-
midine (3H-T) or tritiated leucine (3H-Leu) incorporations
were assessed by incubating the cells for a further 2 h
period with 3H-T (Amersham-Pharmacia, Du¨bendorf,
Switzerland; 400 nCi/mL) or 3H-Leu (American Radiola-
beled Chemicals, St Louis, MO, USA; 400 nCi/mL)
together with the alamarBlue solution as described earlier,
as a multiplex experiment. After the assessment of cell
survival, the cell layer was washed, precipitated with 10%
trichloracetic acid, and the precipitate was dissolved in 1%
sodium dodecyl sulfate/0.1 N NaOH. Radioactivity was
counted using a b-counter (WinSpectral, Wallac Regens-
dorf, Switzerland) after the addition of a scintillation
cocktail (Optiphase HI-Safe, PerkinElmer). The values for
treated cells were compared with the values for control
cells incubated without complexes. Experiments were
conducted in triplicate wells and repeated at least twice.
Determination of phototoxicity
Cells were grown in 96-well cell culture plates (Costar)
until they were 20% confluent. The culture medium was
replaced with complete medium containing ruthenium
complexes 1–8 at 5 lM concentration and the cells were
exposed to the complexes for 24 h. Thereafter, cells were
irradiated at 652 nm using a diode laser (Ceralas 652,
Biolitec, Germany) coupled to a frontal diffuser (Medlight,
Ecublens, Switzerland), at an irradiance of 20 mW/cm2
and light doses ranging between 0.5 and 20 J/cm2.
Experiments were conducted in triplicate. Analysis of cell
viability using the alamarBlue assay as described before
was performed after a further incubation period of 48 h and
the values obtained were compared with the values for
control cells.
Fluorescence microscopy
Cells were grown on histology slides in complete medium
until they were 25% confluent and were then exposed to
compound 5 or 7 (5 lM) for 24 h in the dark. Nuclei were
stained with 40,60-diamidino-2-phenylindolylhydrochloride
(DAPI; 1 mg/L, Roche Diagnostics, Mannheim, Germany)
in phosphate-buffered saline. Alternatively, Lysotracker
(500 nM, Invitrogen, Paisley, UK) or rhodamine 123
(500 lM, Fluka, Buchs, Switzerland) were incubated with
DAPI for the organelle localization studies. Slides were
mounted in phosphate-buffered saline and analyzed under a
fluorescence microscope (Axioplan2, Carl Zeiss, Feldbach,
Switzerland) with filters set at 365 ± 5 nm excitation light
(BP 365/12, FT 395, LP 397) for DAPI, 535 ± 25 nm
excitation light (BP 510–560, FT 580, LP 590) for por-
phyrins, and 470 ± 20 nm excitation light (BP 450–490,
FT 510, BP 515–565) for Lysotracker and rhodamine 123.
Results
Syntheses
The dinuclear arene ruthenium complexes [Ru(g6-are-
ne)Cl2]2 (arene is C6H5Me or p-Pr
iC6H4Me) react in
refluxing methanol with monopyridylporphyrin (mono-3-
pp or mono-4-pp) to give the corresponding mononuclear
complexes 1–4 (Scheme 1).
Similarly, 2 equiv of dinuclear arene ruthenium com-
plexes reacts in refluxing methanol with tetra-3-pp to give
the corresponding tetranuclear arene ruthenium complexes
7 and 8 (Scheme 2).
The previously reported [20–22] complexes 5 and 6 and
the simple monopyridyl arene ruthenium derivatives 9 and
10, depicted in Fig. 1, were also included in this study.
The 1H NMR spectra of 1–8 were recorded in DMSO-d6
owing to the low solubility of the complexes in water. All
complexes show, in addition to the signals of the corre-
sponding g6-arene signals for the organometallic parts and
two multiplets centered at d = 8.2 and d = 7.8 ppm for the
phenyl groups, the typical three-signal pattern for the
pyrrolyl and pyridyl protons of the porphyrin unit between
d = 9.5 and d = 8.0 ppm, the pyridyl signals being
observed as two doublets, while the pyrrolyl protons give a
singlet. The two NH protons appear upfield as a singlet at
d * -2.9 ppm.
The IR spectra of 1–8 in KBr pellets show weak N–H
stretching vibrations above 3,300 cm-1 in the high wave-
number region. In the mid-frequency region, porphyrin
skeletal stretching and C=N pyrrole stretching bands
are observed at 1,720, 1,650, 1,600, 1,510, 1,460, and
1,400 cm-1, while in the low wavenumber region, the in-
plane bending, out-of-plane bending, ring rotation, and ring
torsion modes of the pyridylporphyrin skeletal are found at
970, 800, 730, and 700 cm-1.
Wavelengths and extinction coefficients of absorption
bands of 1–8 in dichloromethane are presented in Table 1,
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together with fluorescence and singlet oxygen quantum
yields measured after 414-nm excitation. Like the parent
porphyrins, complexes 1–8 exhibit the four Q bands
between 510 and 650 nm and the intense Soret-type band
around 420 nm. Interestingly, despite structural differ-
ences, all tetrapyridyl derivatives (5–8) show similar
oxygen quantum yields in methanol.
Biological assays
The growth inhibition exerted by these new organometallic
porphyrin complexes was investigated in vitro using human
Me300 melanoma cells. Cells were exposed for 72 h to
increasing concentrations of compounds 1–10 and their
survival was determined using the alamarBlue assay. In the
absence of laser exposure (dark toxicity), compounds 1–4,
bearing one ruthenium moiety, inhibited poorly the
growth of melanoma cells, while compounds 5–8, bearing
four ruthenium moieties, were potent growth inhibitors
(IC50 * 20 lM for 5, 7, and 8 and IC50 * 10 lM for 6).
The corresponding monopyridyl arene ruthenium deriva-
tives 9 and 10 did not display any cytotoxic effect (Fig. 2).
The potential of the complexes to decrease cell growth
by inhibiting the synthesis of DNA and/or proteins was also
determined. Me300 melanoma cells were incubated with
complexes 6 and 8 at 5 lM concentrations (below IC50)
and the incorporations of 3H-T or 3H-Leu were evaluated at
different incubation times. Exposure of the cells to these
molecules demonstrated that they inhibited thymidine
incorporation (DNA synthesis) very rapidly (less than 3 h)
and that thymidine incorporation was completely inhibited
after 5 h of cell exposure (Fig. 3a). Leucine incorporation
was only slightly blocked by the complexes (Fig. 3b).
Table 1 UV–vis maximum absorption and molar extinction coefficients [k (e 9 10-3 M-1 cm-1)] determined in CH2Cl2, fluorescence quantum
yields at 648 nm (/f
648) in MeOH and singlet oxygen quantum yields /1O2 in EtOH
Complex Soret band Q band IV Q band III Q band II Q band I /f
648 (%) /1O2 (%)
1 418 (167.2) 515 (12.7) 551 (7.1) 590 (5.4) 646 (4.5) 10.9 49
2 419 (153.6) 515 (10.0) 551 (5.8) 589 (4.6) 645 (3.7) 9.8 81
3 419 (156.7) 515 (10.0) 550 (5.1) 589 (4.2) 645 (3.4) 9.5 41
4 418 (162.4) 515 (11.3) 549 (5.3) 589 (4.1) 646 (4.0) 11.3 64
5 423 (156.5) 516 (13.6) 550 (7.7) 590 (6.7) 645 (4.4) 7.4 66
6 422 (188.2) 515 (19.8) 550 (9.1) 590 (6.9) 645 (4.8) 7.9 76
7 423 (151.1) 516 (12.2) 550 (6.7) 590 (5.5) 646 (4.3) 8.1 70
8 423 (158.4) 516 (11.1) 550 (5.1) 589 (4.6) 646 (2.9) 7.6 79
See ‘‘Materials and methods’’ for the description of the complexes
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b tritiated leucine (3H-Leu) was
performed after different times
of incubation
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Similarly, the phototoxic efficacy of the porphyrin
complexes was assessed at 5 lM concentrations. Cells
were incubated for 24 h with compounds 1–8 before irra-
diation at 652 nm (20 mW/cm2), then alamarBlue assay
was performed after a further incubation of 48 h. The
phototoxic efficacy of the compounds was related to the
porphyrin structures and not to the nature of the arene
moieties. For the tetranuclear arene ruthenium 3-pyridyl-
porphyrins 7 and 8, LD50 was less than 0.5 J/cm
2, for the
mononuclear arene ruthenium 3-pyridylporphyrins 3 and 4,
LD50 = 2.5 J/cm
2, for tetranuclear arene ruthenium
4-pyridylporphyrins 5 and 6, LD50 = 5.0 J/cm
2, and for
mononuclear arene ruthenium 4-pyridylporphyrins 1 and 2,
LD50 = 10 J/cm
2 (Fig. 4).
The uptake by Me300 melanoma cells of the tetranu-
clear compounds 5 and 7 at 5 lM concentration was
determined after 24 h of cell exposure, using fluorescence
microscopy (Fig. 5). The fluorescence associated with
porphyrins 5 and 7 appears red, whereas cell nuclei appear
blue with DAPI counterstaining. The two compounds dis-
played a very different pattern of accumulation in the
cytoplasm of melanoma cells. Compound 5 was visible as
red fluorescent spots, as previously described [20], while
the fluorescence of compound 7 was homogenously dis-
tributed in the cytoplasm. For both compounds, nuclear
fragmentation was not observed, suggesting the absence
of cell apoptosis during this time course. Intracellular
localization studies with fluorescent reporter probes for
lysosomes and mitochondria (Lysotracker and rhodamine
123, respectively) revealed that 5 and 7 did not preferen-
tially localize in these organelles (results not shown).
Discussion
Dual chemotherapeutic agents combining two independent
therapeutic modalities with anticancer potential are
advantageous for therapeutic efficacy and to overcome
resistance mechanisms. In the present study, our aim was to
develop molecules able to combine the photosensitizing
properties of porphyrins with the chemotherapeutic effects
of ruthenium, as potential drug candidates for cancer
therapy. Thus, new porphyrin arene ruthenium complexes,
bearing one or four arene ruthenium moieties coupled to 4-
pyridylporphyrin or 3-pyridylporphyrin, were synthesized
according to a previously described procedure [20].
All compounds presented similar spectroscopic proper-
ties. The electron-withdrawing character of the pyridyl
groups in the 3-pyridylporphyrin derivatives was stronger
than in the 4-pyridylporphyrin systems; thus, the ratios of
intensities of bands III and II (e3-pp/e4-pp) followed the same
order [26]. Arene ruthenium groups increased the hydro-
philicity of the highly hydrophobic pyridylporphyrin
ligands and thus allowed their solubilization in polar
organic solvents, whereas the free pyridylporphyrins were
nearly insoluble in polar solvents, including DMSO.
The evaluation of such compounds as chemotherapeutic
agents and phototherapeutic agents in photodynamic ther-
apy was done using human Me300 melanoma cells. All
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Fig. 4 Photodynamic activity of compounds 1–8 in human Me300
melanoma cells. Cells were exposed to compounds 1–8 (5 lM) in the
dark for 24 h, before being exposed to increasing doses of light at
652-nm wavelength. Then the amount of metabolically active cells
was determined 48 h later by the alamarBlue assay. Cells not exposed
to the compounds, but irradiated, were used as controls
Fig. 5 Accumulation of tetranuclear arene ruthenium porphyrin
compounds in human Me300 melanoma cells by fluorescence
microscopy. Cells were grown on histology glass slides and were
exposed to compound 5 (a) or 7 (b) at 5 lM concentration for 24 h in
the dark. Compounds 5 and 7 appear as red fluorescence spots and cell
nuclei as blue fluorescence after 40,60-diamidino-2-phenylindolylhy-
drochloride counterstaining
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compounds possessed distinct cell growth inhibitory pro-
files, which was always linked to the functionalization of
the tetrapyrrole ring. Compounds bearing only one arene
ruthenium moiety were only slightly cytotoxic in the
absence of laser irradiation, displaying LC50 values greater
than 100 lM, whereas tetranucleated compounds were
good inhibitors of cell growth, presenting LD50 values of
20 lM or less. The porphyrin ring also seemed to play a
role in this process, maybe responsible for the intracellular
localization of the compounds or increasing their hydro-
phobicity. With the aim to evaluate the intracellular target
of the tetranucleated complexes, kinetic evaluations of
DNA and protein synthesis were assessed at noncytotoxic
concentrations (5 lM) of these compounds. Exposure of
melanoma cells to these molecules demonstrated that they
rapidly inhibit DNA synthesis, while the inhibition of
protein synthesis was a later event and was only partial.
These results suggested a cytotoxic effect of these mole-
cules initially by inhibiting DNA synthesis, which will
induce a decrease of protein synthesis resulting in dimin-
ished cell survival. This pattern corresponds to the effects
described for some platinum or other ruthenium derivatives
known to bind to DNA [27–32].
Photodynamic studies revealed that the nature of the
pyridylporphyrin isomer (3-pyridyl or 4-pyridyl) was more
important than the degree of substitution of the tetrapyrrole
ring. With similar spectroscopic properties, 3-pyridyl
photosensitizers were more photosensitizing than 4-pyridyl
photosensitizers at an equivalent degree of substitution.
The mononuclear 3-pyridyl complexes (3 and 4) were even
better photosensitizers than the tetranuclear 4-pyridyl
complexes (5 and 6). Hence, the best combination (com-
pounds 7 and 8) was composed of four arene ruthenium
groups coordinated to the tetradentate tetra-3-pp ligand.
Such compounds only needed very low light doses (less
than 0.5 J/cm2) and low concentration (5 lM) to induce
cell death.
Fluorescence microscopy studies demonstrated that the
tetranuclear complexes presented a very different pattern of
accumulation in the cytoplasm depending on the particular
isomer of tetrapyridylporphyrin. Compound 5, bearing a
tetra-4-pp group, was found as red fluorescent spots in the
cell cytoplasm as previously observed [20], while the
fluorescence associated with the tetra-3-pp derivative (7)
was found to be homogenously distributed in the cytoplasm.
We associated this pattern of cellular localization with the
important differences in photosensitizing efficacy. We
observed that free tetra-3-pp was more soluble in DMSO
than free tetra-4-pp. This information suggests that the
increased hydrophobicity of the latter compound resulted in
an increased propensity to aggregate in an aqueous med-
ium, as observed for compound 5 under the microscope,
resulting in a lower photodynamic efficacy, since aggre-
gates decrease the formation of singlet oxygen [33].
In conclusion, we prepared a series of new organome-
tallic-modified porphyrin compounds and showed that they
present a synergistic effect with good properties of both the
arene ruthenium chemotherapeutic effect and the porphyri-
nic photosensitizing efficiency at low concentration (5 lM)
and low dose of red light (less than 0.5 J/cm2 at 652 nm).
Moreover, we showed that the ruthenium porphyrin com-
pounds accumulated differently in the cytoplasm depending
on the particular porphyrin they are composed of, inducing
different phototoxicity, however with identical spectro-
scopic properties.
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